Dipeptide levels in CKD
Research type
Research Study
Full title
A research study to investigate dipeptide and metabolite levels in blood from chronic kidney disease (CKD) patients
IRAS ID
329280
Contact name
Stanley Fan
Contact email
Sponsor organisation
Barts Health NHS Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Itch (pruritus) is common and the Standardised Outcomes in Nephrology (SONG) initiatives flagged that Haemodialysis and Peritoneal Dialysis patients rate this problem highly for research and treatment.
A cream (MC2-25) has been developed (undergoing clinical trials) that is specifically targeting this uraemic itch (CKD-aP). This cream contains dipeptides that neutralize a uraemic toxin called icocyanate which alters (carbamylates) proteins in the skin that is thought to mediate the CKD-aP.
Dipeptides are found naturally in humans but they are difficult to measure and the level in patients with kidney disease (CKD) is unknown.
This study is to determine if dipeptides (and their metabolites) are detectable in patients with CKD.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
23/WM/0168
Date of REC Opinion
28 Jul 2023
REC opinion
Favourable Opinion